ArticleLeukemia2021

Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age.

Elias K Mai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.